1 story in the last 7 days
The latest novo nordisk news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks novo nordisk across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.

Novo Nordisk CEO Mike Doustdar said the company's obesity drugs could expand into longevity research and aesthetic medicine. Doustdar pointed to research suggesting semaglutide, the main ingredient in Ozempic and Wegovy, may do more than help patients lose weight. The comments came during an interview at the American Diabetes Association conference in New Orleans.
Summaries by ByteBrief